BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21560226)

  • 1. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
    Mrakotsky CM; Silverman LB; Dahlberg SE; Alyman MC; Sands SA; Queally JT; Miller TP; Cranston A; Neuberg DS; Sallan SE; Waber DP
    Pediatr Blood Cancer; 2011 Sep; 57(3):492-8. PubMed ID: 21560226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01.
    Waber DP; McCabe M; Sebree M; Forbes PW; Adams H; Alyman C; Sands SA; Robaey P; Romero I; Routhier MÈ; Girard JM; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2013 Nov; 60(11):1785-91. PubMed ID: 23832430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia.
    Daniel LC; Li Y; Kloss JD; Reilly AF; Barakat LP
    Support Care Cancer; 2016 Sep; 24(9):3897-906. PubMed ID: 27108263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia.
    Hurwitz CA; Silverman LB; Schorin MA; Clavell LA; Dalton VK; Glick KM; Gelber RD; Sallan SE
    Cancer; 2000 Apr; 88(8):1964-9. PubMed ID: 10760775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
    Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
    J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.
    Waber DP; Carpentieri SC; Klar N; Silverman LB; Schwenn M; Hurwitz CA; Mullenix PJ; Tarbell NJ; Sallan SE
    J Pediatr Hematol Oncol; 2000; 22(3):206-13. PubMed ID: 10864051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
    Silverman LB; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Arkin S; Declerck L; Cohen HJ; Sallan SE
    Blood; 2001 Mar; 97(5):1211-8. PubMed ID: 11222362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroids, behavior, and quality of life in children treated for acute lymphoblastic leukemia; a multicentered trial.
    Pound CM; Clark C; Ni A; Athale U; Lewis V; Halton JM
    J Pediatr Hematol Oncol; 2012 Oct; 34(7):517-23. PubMed ID: 22735884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of adrenal reserve in children with acute lymphocytic leukemia treated with prednisone or dexamethasone.
    Kuperman H; Odone Filho V; Cristofani LM; Assis de Almeida MT; Setian N; Damiani D
    Horm Res Paediatr; 2012; 78(2):73-80. PubMed ID: 22922775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the neurobehavioral side effects of dexamethasone in pediatric acute lymphoblastic leukemia.
    Warris LT; van den Akker EL; Aarsen FK; Bierings MB; van den Bos C; Tissing WJ; Sassen SD; Veening MA; Zwaan CM; Pieters R; van den Heuvel-Eibrink MM
    Psychoneuroendocrinology; 2016 Oct; 72():190-5. PubMed ID: 27448086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
    Athale UH; Siciliano SA; Crowther M; Barr RD; Chan AK
    Br J Haematol; 2005 Jun; 129(6):803-10. PubMed ID: 15953008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does dexamethasone induce more neuropsychological side effects than prednisone in pediatric acute lymphoblastic leukemia? A systematic review.
    Warris LT; van den Heuvel-Eibrink MM; den Hoed MA; Aarsen FK; Pieters R; van den Akker EL
    Pediatr Blood Cancer; 2014 Jul; 61(7):1313-8. PubMed ID: 24532490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.
    Mattano LA; Sather HN; Trigg ME; Nachman JB
    J Clin Oncol; 2000 Sep; 18(18):3262-72. PubMed ID: 10986059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: a controlled study comparing prednisone versus dexamethasone in induction phase.
    Saracco P; Bertorello N; Farinasso L; Einaudi S; Barisone E; Altare F; Corrias A; Pastore G
    J Pediatr Hematol Oncol; 2005 Mar; 27(3):141-4. PubMed ID: 15750445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for steroid-induced affective disorder in children with leukemia.
    Muriel AC; Burgers DE; Treyball AN; Vrooman LM; Adolf E; Samsel C
    Pediatr Blood Cancer; 2021 May; 68(5):e28847. PubMed ID: 33305874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Mercaptopurine Adherence in Pediatric Acute Lymphoblastic Leukemia: A Survey Study From the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium.
    Kahn JM; Stevenson K; Beauchemin M; Koch VB; Cole PD; Welch JJG; Gage-Bouchard E; Karsenty C; Silverman LB; Kelly KM; Bona K
    J Pediatr Hematol Oncol Nurs; 2023; 40(1):17-23. PubMed ID: 36221984
    [No Abstract]   [Full Text] [Related]  

  • 18. Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design.
    van Hulst AM; Verwaaijen EJ; Fiocco MF; Pluijm SMF; Grootenhuis MA; Pieters R; van den Akker ELT; van den Heuvel-Eibrink MM
    BMC Pediatr; 2021 Sep; 21(1):427. PubMed ID: 34579671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bony morbidity in children treated for acute lymphoblastic leukemia.
    Strauss AJ; Su JT; Dalton VM; Gelber RD; Sallan SE; Silverman LB
    J Clin Oncol; 2001 Jun; 19(12):3066-72. PubMed ID: 11408503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
    Bostrom BC; Sensel MR; Sather HN; Gaynon PS; La MK; Johnston K; Erdmann GR; Gold S; Heerema NA; Hutchinson RJ; Provisor AJ; Trigg ME;
    Blood; 2003 May; 101(10):3809-17. PubMed ID: 12531809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.